Age group | <65 years (n = 89) | ≥65 years (n = 76) | ||||
P+ L (n = 47) | L (n = 42) | P + L (n = 37) | L (n = 39) | |||
Median age (range), years | 55.0 (41–64) | 56.5 (38–64) | 72.0 (65–89) | 70.0 (65–84) | ||
ECOG performance status | ||||||
0 | 26 (55.3 %) | 23 (54.8 %) | 20 (54.1 %) | 22 (56.4 %) | ||
1 | 21 (44.7 %) | 19 (45.2 %) | 17 (45.9 %) | 17 (43.6 %) | ||
Disease stage | ||||||
IIIB | 1 (2.1 %) | 1 (2.4 %) | 1 (2.7 %) | 0 | ||
IV | 46 (97.9 %) | 41 (97.6 %) | 36 (97.3 %) | 39 (100.0 %) | ||
Disease sitea | ||||||
Bone-only | 9 (19.2 %) | 3 (7.1 %) | 8 (21.6 %) | 9 (23.1 %) | ||
Visceral | 19 (40.4 %) | 22 (52.4 %) | 18 (48.7 %) | 21 (53.9 %) | ||
Other | 19 (40.4 %) | 17 (40.5 %) | 11 (29.7 %) | 9 (23.1 %) | ||
Prior systemic treatment | ||||||
None | 24 (51.1 %) | 23 (54.8 %) | 20 (54.1 %) | 14 (35.9 %) | ||
Yes | 23 (48.9 %) | 19 (45.2 %) | 17 (45.9 %) | 25 (64.1 %) | ||
Histological type | Ductal carcinoma (n = 117) | Lobular carcinoma (n = 37) | ||||
P+ L (n = 63) | L (n = 54) | P + L (n = 18) | L (n = 19) | |||
Median age (range), years | 63 (41–89) | 65 (42–84) | 60 (50–74) | 62 (38–78) | ||
ECOG performance status | ||||||
0 | 36 (57.1 %) | 29 (53.7 %) | 9 (50.0 %) | 14 (73.7 %) | ||
1 | 27 (42.9 %) | 25 (46.3 %) | 9 (50.0 %) | 5 (26.3 %) | ||
Disease stage | ||||||
IIIB | 2 (3.2 %) | 1 (1.9 %) | 0 | 0 | ||
IV | 61 (96.8 %) | 53 (98.1 %) | 18 (100.0 %) | 19 (100.0 %) | ||
Disease sitea | ||||||
Bone-only | 11 (17.5 %) | 8 (14.8 %) | 4(22.2 %) | 3 (15.8 %) | ||
Visceral | 28 (44.4 %) | 30 (55.6 %) | 8 (44.4 %) | 7 (36.8 %) | ||
Other | 24 (38.1 %) | 16 (29.6 %) | 6 (33.3 %) | 9 (47.4 %) | ||
Prior systemic treatment | ||||||
None | 36 (57.1 %) | 26 (48.1 %) | 6 (33.3 %) | 7 (36.8 %) | ||
Yes | 27 (42.9 %) | 28 (51.9 %) | 12 (66.7 %) | 12 (63.2 %) | ||
Prior systemic treatment | None (n = 81) | Yes (n = 84) | ||||
P+ L (n = 44) | L (n = 37) | P + L (n = 40) | L (n = 44) | |||
Median age (range), years | 63.0 (41–83) | 62.0 (43–76) | 60.0 (46–89) | 65.5 (38–84) | ||
ECOG performance status | ||||||
0 | 26 (59.1 %) | 18 (48.6 %) | 20 (50.0 %) | 27 (61.4 %) | ||
1 | 18 (40.9 %) | 19 (51.4 %) | 20 (50.0 %) | 17 (38.6 %) | ||
Disease stage | ||||||
IIIB | 1 (2.3 %) | 0 | 1 (2.5 %) | 1 (2.3 %) | ||
IV | 43 (97.7 %) | 37 (100.0 %) | 39 (97.5 %) | 43 (97.7 %) | ||
Disease sitea | ||||||
Bone-only | 6 (13.6 %) | 5 (13.5 %) | 11 (27.5 %) | 7 (15.9 %) | ||
Visceral | 24 (54.6 %) | 19 (51.4 %) | 13 (32.5 %) | 24 (54.6 %) | ||
Other | 14 (31.8 %) | 13 (35.1 %) | 16 (40.0 %) | 13 (29.6 %) | ||
Disease sitea | Bone-only (n = 29) | Visceral (n = 80) | Other (n = 56) | |||
P + L (n = 17) | L (n = 12) | P + L (n = 37) | L (n = 43) | P + L (n = 30) | L (n = 26) | |
Median age (range), years | 63.0 (46–89) | 69.0 (42–73) | 63.0 (41–83) | 64.0 (38–84) | 62.0 (52–78) | 62.0 (43–75) |
ECOG performance status | ||||||
0 | 11 (64.7 %) | 10 (83.3 %) | 19 (51.4 %) | 19 (44.2 %) | 16 (53.3 %) | 16 (61.5 %) |
1 | 6 (35.3 %) | 2 (16.7 %) | 18 (48.6 %) | 24 (55.8 %) | 14 (46.7 %) | 10 (38.5 %) |
Disease stage | ||||||
IIIB | 0 | 0 | 0 | 0 | 2 (6.7 %) | 1 (3.8 %) |
IV | 17 (100.0 %) | 12 (100.0 %) | 37 (100.0 %) | 43 (100.0 %) | 28 (93.3) | 25 (96.2) |
Prior systemic treatment | ||||||
None | 6 (35.3 %) | 5 (41.7 %) | 24 (64.9 %) | 19 (44.2 %) | 14 (46.7 %) | 13 (50.0 %) |
Yes | 11 (64.7 %) | 7 (58.3 %) | 13 (35.1 %) | 24 (55.8 %) | 16 (53.3 %) | 13 (50.0 %) |